Last reviewed · How we verify
IV Magnesium Sulfate
Magnesium sulfate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuronal excitability and vascular smooth muscle contractility.
Magnesium sulfate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuronal excitability and vascular smooth muscle contractility. Used for Seizure prophylaxis in preeclampsia and eclampsia, Acute myocardial infarction with arrhythmias, Severe acute asthma exacerbation (bronchodilation).
At a glance
| Generic name | IV Magnesium Sulfate |
|---|---|
| Also known as | IV MgSO4, Magnesium Sulfate IV |
| Sponsor | University Hospitals Cleveland Medical Center |
| Drug class | Electrolyte supplement / anticonvulsant |
| Target | NMDA receptor antagonist; calcium channel blocker (non-selective) |
| Modality | Small molecule |
| Therapeutic area | Obstetrics; Neurology; Cardiology; Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Magnesium blocks calcium influx into cells and antagonizes N-methyl-D-aspartate (NMDA) receptors, leading to decreased neuromuscular transmission and vasodilation. This mechanism underlies its use in seizure prophylaxis (particularly eclampsia/preeclampsia), cardiac arrhythmia management, and as a bronchodilator in acute asthma exacerbations.
Approved indications
- Seizure prophylaxis in preeclampsia and eclampsia
- Acute myocardial infarction with arrhythmias
- Severe acute asthma exacerbation (bronchodilation)
- Hypomagnesemia correction
Common side effects
- Flushing
- Hypotension
- Hypermagnesemia (with overdose)
- Muscle weakness
- Respiratory depression (at high doses)
Key clinical trials
- Comparison of Fentanyl and Magnesium to Control Reflex Hemodynamics in Patients Aged 50 and Older (NA)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Magnesium as an Adjuvant Agent for Postoperative Pain (PHASE4)
- Magnesium Sulfate Versus Other Anesthesia Drugs to Reduce Agitation After Adenotonsillectomy in Pediatric Patients (NA)
- Rate, Rhythm or Risk Control for New-onset Supraventricular Arrhythmia During Septic Shock: a Randomized Controlled Trial (NA)
- Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients (PHASE4)
- Intravenous Administration of Magnesium Sulfate in Laparoscopic Hysterectomy Cases (NA)
- Magnesium Trial in Acute Asthma in Emergency Department (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Magnesium Sulfate CI brief — competitive landscape report
- IV Magnesium Sulfate updates RSS · CI watch RSS
- University Hospitals Cleveland Medical Center portfolio CI